Can we change the prognosis for patients with Crohn's disease? : comments of the results of the EXTEND trial

Abstract

The EXTEND trial focused on the efficacy of one-year treatment with adalimumab in achieving mucosal healing in patients with Crohn´s disease. The study results confirmed that mucosal healing is an important surrogate marker of long-term remission.

The EXTEND trial has altered the therapeutic approach to patients with Crohn´s disease, demonstrating the benefit of effective anti-TNF therapy when continued beyond the clinical remission.

Keywords

• biological therapy
• adalimumab
• mucosal healing